🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
AMGN
NASDAQ
🇺🇸 US
Amgen Inc.
Pharmaceuticals
21Score
DipBuster Score™
$366.05
$0.19 (-0.05%)
Live price · Source: Yahoo
52-Week Position
$269.77
79% of range
$391.29
Beta
0.403
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.403
52W High$391.29
52W Low$269.77
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Neutral
Mid-Range Position (79% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position79% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.403
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Amgen Inc. (AMGN), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-05-19 | Klotman Mary E. | BUY | 665 |
| 2026-05-19 | Drake Michael V | BUY | 665 |
| 2026-05-19 | Druker Brian | BUY | 665 |
| 2026-05-19 | Austin Wanda M | BUY | 665 |
| 2026-05-19 | Ishrak Omar | BUY | 665 |
| 2026-05-19 | Garland Greg C. | BUY | 665 |
| 2026-05-19 | Jacks Tyler | BUY | 665 |
| 2026-05-19 | Kullman Ellen Jamison | BUY | 665 |
| 2026-05-19 | Miles Amy E | BUY | 665 |
| 2026-05-19 | Holley Charles M | BUY | 665 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.403
Dividend/yrNone
52W High$391.29
52W Low$269.77
52-Week Range
$269.77Now$391.29
79% through annual range
From 52W High−6.5%
From 52W Low+35.7%
📖 Plain English Summary
Amgen Inc. is at 79% of its 52-week range. Beta 0.403 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for AMGN
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — AMGN
Heuristic · balance sheet, insider filings, price data, academic research
Amgen Inc. — DipBuster Score 21/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Amgen Inc. free
Add AMGN to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
8/25
Momentum & Volume
8/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
2
/100 · NEUTRAL
dip depth
2/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 21/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The compa…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Robert A. Bradway
Staff
31,500 employees
Website